Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Revenue of Zealand Pharma A/S (ZEAL.CO)
Revenue in 2023 (TTM): $49.73 M
According to Zealand Pharma A/S's latest financial reports the company's current revenue (TTM) is $49.73 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Zealand Pharma A/S
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $49.73 M | $42.85 M | $-77,320,846 | $-102,845,834 | $-102,102,127 |
| 2022 | $15.09 M | $10.63 M | $-96,519,683 | $-141,028,781 | $-140,095,738 |
| 2021 | $42.45 M | $25.21 M | $-141,321,998 | $-148,993,815 | $-147,718,370 |
| 2020 | $51.26 M | $38.12 M | $-126,512,280 | $-121,821,239 | $-122,847,862 |
| 2019 | $6 M | $5.94 M | $-81,630,167 | $-83,667,309 | $-82,922,151 |
| 2018 | $5.51 M | $-20,639,968 | $-97,068,975 | $90.69 M | $84.34 M |
| 2017 | $20.28 M | $18.16 M | $-35,731,007 | $-40,300,466 | $-39,502,498 |
| 2016 | $34.06 M | $29.5 M | $-17,158,939 | $-23,128,035 | $-22,330,066 |
| 2015 | $27.23 M | $24 M | $-12,283,205 | $-17,385,852 | $-16,533,476 |
| 2014 | $22.31 M | $20.31 M | $-9,704,170 | $-10,517,228 | $-9,429,088 |
| 2013 | $953.79 K | $827.28 K | $-25,631,190 | $-26,648,673 | $-26,660,425 |
| 2012 | $32.44 M | $30.12 M | $6.29 M | $5.28 M | $5.28 M |
| 2011 | $20.64 M | $20.63 M | $2.82 M | $1.94 M | $988.47 K |
| 2010 | $12.67 M | $12.67 M | $-15,171,706 | $-15,180,847 | $-15,180,847 |
| 2009 | $3.67 M | $3.67 M | $-10,434,529 | $-10,984,402 | $-11,611,025 |
| 2008 | $8.16 M | $8.16 M | $-6,483,713 | $-4,894,015 | $-4,894,015 |
| 2007 | $8.69 M | $8.69 M | $-9,071,743 | $-7,979,687 | $-7,979,687 |